TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. All participants must be 18 years or older.~2. All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.~3. Individuals with medically stable Parkinson's disease (in the opinion of the investigator).~4. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.~5. Absence of dementia in all subjects, as determined by pre-scanning cognitive assessment.~6. Control subjects who are able to undergo MRS~Exclusion Criteria:~1. Inability to undergo MRI scanning without sedation~2. Medically unstable conditions in any group as determined by the investigators~3. Pregnant or lactating or those women of child-bearing age that are not using acceptable forms of contraception~4. Diagnosis of asthma that is presently being treated with ANY medication, or past history of asthma/bronchospasm resulting in an emergency room visit, hospitalization or treatment~5. Unable to adhere to study protocol for whatever reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NAC in PD (Type: EXPERIMENTAL): single intravenous administration of N-acetylcysteine in PD patients
- NAC in GD (Type: EXPERIMENTAL): single intravenous administration of N-acetylcysteine in GD patients
- NAC in controls (Type: EXPERIMENTAL): single intravenous administration of N-acetylcysteine in control subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lab School Day Study for CONCERTA of Older Children With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ADHD diagnosis of all subtypes (except Not Otherwise Specified)~* Patients with total or subscale Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS-IV) scores \> =90th percentile relative to the general population of children by age and gender~* Patients currently receiving ADHD medication must be inadequately managed on their current stimulant dose and meet this criteria at the screening visit~* Ability to read and understand English~* Ability to attend school regularly.~Exclusion Criteria:~* Estimated Full Scale IQ score of 80 or below~* Severe Learning Disability~* History of, or current, primary diagnosis of: severe anxiety disorder, conduct disorder, psychotic disorders, pervasive developmental disorder, eating disorder, obsessive-compulsive disorder, sleep disorder, major depressive disorder, bipolar disorder, substance use disorder, chronic tic disorder, personal or family history of Tourette's syndrome~* Weight \< 3rd percentile for age~* History of hospitalization for treatment of a mood, anxiety, or psychotic disorder~* History of failed response to methylphenidate.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CONCERTA (methylphenidate HCl) / Placebo Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
- 2 (Type: EXPERIMENTAL): Placebo/ CONCERTA (methylphenidate HCl) Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Changing Talk Online (CHATO) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Nursing Homes that serve people with dementia.~* Nursing Homes that have internet available for staff to complete the CHATO training.~* Nursing Homes that are willing to complete leadership interviews and surveys.~* CNAs and nurses who are permanent employees and who provide direct care at least 8 hours weekly will be invited to complete the CHATO training, available by URL link.~* Other personnel, such as housekeeping, dietary, and administrators may also participate. Participation by as many staff as possible is desired to achieve facility-wide communication change.~* Aggregate, deidentified data for residents with Alzheimer's disease or non-Alzheimer's dementia documented on the MDS Active Diagnoses list.~Exclusion Criteria~* Assisted Living facilities or other types of facilities are excluded due to lack of MDS data as well as NHs that previously participated in the CHAT study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Three nursing homes will receive the training and three control nursing homes will complete assessments, but not receive the training.
- Waitlist Control (Type: ACTIVE_COMPARATOR): After the intervention group takes the training, the waitlist control group will crossover and take the training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pitavastatin in a Real-world Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients in need of statin treatment who are taking or are planning to take Livalo tablets, or who are taking other statins or are planning to change to Livalo tablets.~Exclusion Criteria:~* Patients with hypersensitivity to pitavastatin~* Patients with active liver disease or untranslated transaminase levels Patients with a constant rise in~* Patients with severe liver failure or biliary obstruction and patients with cholestasis~* Patients who are receiving cyclosporine~* Myopathy patients~* Pregnant women or women of childbearing age and lactating women~* Children~* Patients with genetic problems, such as galactose intolerance, Lapp lactose deficiency or glucose-galactose~* Patients deemed inappropriate by the investigator

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject or authorized representative has provided informed consent.~* Subject is ≥ 18 years old.~* Subject is scheduled for nonemergent surgery where a topical hemostatic agent would be used to control bleeding emanating from a tissue bed following organ dissection or removal or a bleeding tumor tissue bed following resection or dissection, via an open approach.~* Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.~* Subject has an appropriate Target Bleeding Site (TBS) during the surgical procedure.~* TBS bleeding assessment is Type 2 or 3 (refer to table in protocol).~Exclusion Criteria:~* Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding.~* Subject has an estimated life expectancy of less than 6 months.~* Subject is scheduled for another planned surgery and the subsequent surgery would jeopardize the previous application of study treatment.~* Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death.~* Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with the study.~* Subject has an active local infection at the TBS.~* The investigator determines that participation in the study may jeopardize teh safety or welfare of the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Veriset™ Hemostatic Patch (Type: EXPERIMENTAL): Topical hemostat

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Infusion of Terlipressin in Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Septic shock~* vasopressor support to maintain mean arterial pressure (MAP) between 65 and 75 mmHg despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18 mmHg and central venous pressure = 8-12 mmHg)~Exclusion Criteria:~* Pregnancy~* Present cardiac dysfunction~* Present or suspected acute mesenteric ischemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Terlipressin
- 2 (Type: EXPERIMENTAL): Vasopressin
- 3 (Type: ACTIVE_COMPARATOR): titrated norepinephrine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients will have a diagnosis of CLL, Small Lymphocytic Lymphoma (SLL), or CD20 positive low-grade lymphoproliferative disorder.~2. All patients with untreated Rai stage III-IV are eligible for this protocol. Prior treatment with single-agent rituximab permitted. OR Patients with untreated Rai stage 0-II who meet one or more criteria for active disease as defined by the International Working Group for CLL (IWCLL). Prior treatment with single-agent rituximab permitted.~3. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.~4. Patients must have adequate renal and hepatic function (creatinine \<2mg%, bilirubin \<2mg%). Patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman.~5. Patients may not receive other concurrent chemotherapy, radiotherapy, or immunotherapy. Localized radiotherapy to an area not compromising bone marrow function does not apply.~6. Patients must be 16 years of age or older.~7. Patients must sign informed consent indicating that they are aware of the investigational nature of this study according to the policies of the MD Anderson Cancer Center Institutional Review Board (MDACC IRB).~Exclusion Criteria:~N/A

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fludarabine, Cyclophosphamide, Rituximab (Type: EXPERIMENTAL): Fludarabine 25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Cyclophosphamide 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Rituximab 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 6- 59 months with cough, difficult breathing and chest indrawing~* Written informed consent from the caretaker~Exclusion Criteria:~* Children with known heart disease~* Children on medication with Zinc supplements~* Children with obstructive air way disease~* Children with active measles~* Known intolerance or allergy to zinc or zinc-containing products

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Zinc (Type: EXPERIMENTAL): Zinc acetate
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with normal renal function or renal impairment (mild, moderate, severe or end stage renal disease (ESRD) requiring haemodialysis)~* Body mass index maximum 40.0 kg/m\^2~Exclusion Criteria:~* Subject with any disease or condition which the Investigator feels would interfere with the trial except for conditions associated with renal impairment in the group of subjects with compromised renal function. Diabetes mellitus can be accepted in the group of patients with renal impairment, but not in subjects with normal renal function~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Significant history of alcoholism or drug/chemical abuse~* Not able or willing to refrain from smoking during the inpatient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ESRD (Type: EXPERIMENTAL): None
- Mild (Type: EXPERIMENTAL): None
- Moderate (Type: EXPERIMENTAL): None
- Normal (Type: EXPERIMENTAL): None
- Severe (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 18 and 75~* Patients with essential hypertension {95 mmHg ≤ sitDBP\< 115 mmHg at the end of placebo run-in treatment period}~Exclusion Criteria:~* Patients with mean sitSBP ≥ 200 mmHg~* Patients with known hypersensitivity to Dihydropyridine or angiotensin II receptor blockers~* Patients with secondary hypertension or suspected secondary hypertension~* Patients with malignant hypertension~* Patients who have received any medications with possible interactions with study drugs~* Patients with uncontrolled diabetes~* Patients with severe heart disease or severe cerebrovascular disease~* Patients with clinically significant hematological test results, renal disease (serum creatinine) or liver disease (ALT or AST)~* Patients with a history of malignant disease~* Patients with a history of autoimmune disease~* Women with a positive pregnancy test result, breast feeding or intention of pregnancy during the trial~* Patients inappropriate to be included in study population due to other reasons at the discretion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Baseline BMI between 25 and 35~Exclusion Criteria:~* Individuals with current fMRI contraindications (e.g., metal implants, braces)~* Probable current Axis I psychopathology (e.g., major depression disorder, panic disorder, generalized anxiety disorder, bipolar disorder)~* Habitual use of cigarettes or illicit drugs~* Pregnancy or breastfeeding~* Diagnosis of serious medical problems (e.g., diabetes, cardiovascular disease, stroke)~* Current weight loss dieting and/or weight fluctuations great than 10 lbs in the previous 6 weeks~* Do not consume dairy~* Allergy to bromocriptine, dairy, and nuts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Bromocriptine, then Placebo (Type: OTHER): During the first intervention visit, participants receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Following a 2-week washout period, participants return for the second intervention visit, where they receive 2 capsules of placebo (sugar free calcium supplement) matched in shape (circle) and color (white) to bromocriptine. Both bromocriptine and placebo are administered orally.
- Placebo, then Bromocriptine (Type: OTHER): During the first intervention visit, participants receive 2 capsules of placebo (sugar free calcium supplement). Following a 2-week washout period, participants return for the second intervention visit, where they receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Both bromocriptine and placebo are administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients who are at least 12 years of age and who will not have reached their 18th birthday~* Diagnosis of ADHD~* Normal intelligence~Exclusion Criteria:~* Weigh less than 30 kg or more than 85 kg at study entry~* Other relevant psychiatric diagnoses~* Are at serious suicidal risk as determined by the investigator~* Have a history of severe allergies~* Alcohol or drug abuse within the past 3 months~* Are female patients who are pregnant or breast-feeding. Sexually active females must use a medically acceptable method of contraception.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Patients undergoing elective shoulder surgery by one of two surgeons highly experienced in the procedure.~2. Patients are either: Opioid naïve; or Have not taken opiates for one month prior to surgery (tramadol is permissible).~3. Patients have an American Society of Anesthesiology physical status I-III.~Exclusion criteria:~1. Females who are pregnant.~2. Patients who are taking chronic daily opiates for one month prior to surgery except tramadol.~3. Diabetic patients.~4. Patients with creatinine above 1.1mg/dL for females and above 1.3mg/dL for males.~5. Patients with contralateral pneumothorax or diaphragmatic paralysis.~6. Patients with coagulopathy.~7. Patients with clinically significant previous nerve injury in surgical extremity.~8. Patients with an allergy to NSAIDs.~9. Patients who are refusing a block.~10. Patients with a contraindication to ropivacaine, dexamethasone, or interscalene block due to other medical condition such as severe chronic obstructive pulmonary disease (COPD).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone block (Type: EXPERIMENTAL): Blockade with 25 ml ropivacaine 0.5% mixed with 8 mg dexamethasone (0.8 ml), and 5 ml intravenous normal saline
- Dexamethasone IV (Type: ACTIVE_COMPARATOR): Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and intravenous 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml
- Placebo (Type: PLACEBO_COMPARATOR): Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and 5 ml intravenous normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete